Withania somnifera Phytochemicals Confer Neuroprotection by Inhibition of the Catalytic Domain of Human Matrix Metalloproteinase-9

被引:9
作者
Kumar, Gaurav [1 ]
Paliwal, Pankaj [2 ]
Patnaik, Ranjana [1 ]
机构
[1] BHU, Indian Inst Technol, Sch Biomed Engn, Varanasi 221005, UP, India
[2] BHU, Indian Inst Technol, Dept Pharmaceut, Varanasi 221005, UP, India
关键词
Matrix metalloproteinase-9; neurological diseases; Withania somnifera; neuroprotection; molecular docking; in silico; Lipinski's rule of five; BRAIN-BARRIER DISRUPTION; ISCHEMIC-STROKE; ROOT EXTRACT; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; DRUG DISCOVERY; IN-SILICO; PROTEIN; SYSTEM; MODEL;
D O I
10.2174/1570180814666161121111811
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Matrix metalloproteinase-9 (MMP-9) expression is elevated in neurological diseases, and its up-regulation may exert to the pathogenesis of many neurological disorders. Therefore, inhibition of MMP-9 can be of neuroprotective approach. Objective: The present in silico study carried out to explore the possible neuroprotective potential of Withania somnifera phytochemicals through inhibition of MMP-9. Method: Twenty-seven Withania somnifera phytochemicals were selected for this study based on their BBB penetration ability and suitability for Lipinski's rule of five. Further, molecular docking was performed to know whether these phytochemicals inhibit the MMP-9 or not. Results: The results suggest that 17 phytochemicals have the higher affinity for S1'-specificity pocket of the MMP-9 catalytic domain than two inhibitors reverse hydroxamate and quercetin. Because of they directly bound to the active site with lower binding energy and established some hydrogen bonds and hydrophobic interactions with residues critical in mediating inhibition. Conclusion: These phytochemicals have potential as an intrinsically useful oral drug to combat neurological disorders mediated by MMP-9.
引用
收藏
页码:718 / 726
页数:9
相关论文
共 48 条
  • [1] Effects of Withania somnifera in patients of schizophrenia: A randomized, double blind, placebo controlled pilot trial study
    Agnihotri, Akshay P.
    Sontakke, Smita D.
    Thawani, Vijay R.
    Saoji, Anand
    Goswami, Vaidya Shishir S.
    [J]. INDIAN JOURNAL OF PHARMACOLOGY, 2013, 45 (04) : 417 - 418
  • [2] CARCINOGENS AS FRAMESHIFT MUTAGENS - METABOLITES AND DERIVATIVES OF 2-ACETYLAMINOFLUORENE AND OTHER AROMATIC AMINE CARCINOGENS
    AMES, BN
    BARTSCH, H
    MILLER, JA
    GURNEY, EG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1972, 69 (11) : 3128 - &
  • [3] [Anonymous], 2002, PROB SOL, DOI DOI 10.1002/CPHC.201701384
  • [4] Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke
    Anthony, DC
    Ferguson, B
    Matyzak, MK
    Miller, KM
    Esiri, MM
    Perry, VH
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1997, 23 (05) : 406 - 415
  • [5] Characteristics of compounds that cross the blood-brain barrier
    Banks, William A.
    [J]. BMC NEUROLOGY, 2009, 9
  • [6] The Protein Data Bank
    Berman, HM
    Westbrook, J
    Feng, Z
    Gilliland, G
    Bhat, TN
    Weissig, H
    Shindyalov, IN
    Bourne, PE
    [J]. NUCLEIC ACIDS RESEARCH, 2000, 28 (01) : 235 - 242
  • [7] Neuroprotective Effects of Withania somnifera Dunal.: A Possible Mechanism
    Bhatnagar, Maheep
    Sharma, Durgesh
    Salvi, Mahendra
    [J]. NEUROCHEMICAL RESEARCH, 2009, 34 (11) : 1975 - 1983
  • [8] Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia
    Clark, AW
    Krekoski, CA
    Bou, SS
    Chapman, KR
    Edwards, DR
    [J]. NEUROSCIENCE LETTERS, 1997, 238 (1-2) : 53 - 56
  • [9] Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
  • [10] Role of matrix metalloproteinase-9 (MMP-9) in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease
    Duran-Vilaregut, J.
    del Valle, J.
    Manich, G.
    Camins, A.
    Pallas, M.
    Vilaplana, J.
    Pelegri, C.
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2011, 37 (05) : 525 - 537